In this report, we demonstrate that BC-N102, a novel small molecule, exhibited anticancer activity against breast cancer cell lines via interfering with cell cycle regulatory proteins and hormonal receptors signaling in vitro, and exhibited potent antitumor activity at tolerated doses in an ER+ human xenograft breast cancer model. The gene discussed is NR4A1; the disease is breast carcinoma.